Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
UBS
US Department of Justice
Mallinckrodt
Medtronic
Argus Health
Express Scripts
Deloitte
Moodys
QuintilesIMS

Generated: October 17, 2017

DrugPatentWatch Database Preview

ALTOPREV Drug Profile

« Back to Dashboard

Which patents cover Altoprev, and when can generic versions of Altoprev launch?

Altoprev is a drug marketed by Covis Pharma Bv and is included in one NDA. There are three patents protecting this drug.

This drug has thirty-three patent family members in twelve countries.

The generic ingredient in ALTOPREV is lovastatin. There are thirty-three drug master file entries for this compound. Forty-two suppliers are listed for this compound. Additional details are available on the lovastatin profile page.

Summary for Tradename: ALTOPREV

US Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: see list2
Bulk Api Vendors: see list66
Patent Applications: see list6,520
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:ALTOPREV at DailyMed

Pharmacology for Tradename: ALTOPREV

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Covis Pharma Bv
ALTOPREV
lovastatin
TABLET, EXTENDED RELEASE;ORAL021316-001Jun 26, 2002DISCNNoNo► Subscribe► Subscribe ► Subscribe
Covis Pharma Bv
ALTOPREV
lovastatin
TABLET, EXTENDED RELEASE;ORAL021316-003Jun 26, 2002RXYesNo► Subscribe► Subscribe ► Subscribe
Covis Pharma Bv
ALTOPREV
lovastatin
TABLET, EXTENDED RELEASE;ORAL021316-002Jun 26, 2002RXYesNo► Subscribe► Subscribe ► Subscribe
Covis Pharma Bv
ALTOPREV
lovastatin
TABLET, EXTENDED RELEASE;ORAL021316-004Jun 26, 2002RXYesYes► Subscribe► Subscribe ► Subscribe
Covis Pharma Bv
ALTOPREV
lovastatin
TABLET, EXTENDED RELEASE;ORAL021316-003Jun 26, 2002RXYesNo► Subscribe► Subscribe ► Subscribe
Covis Pharma Bv
ALTOPREV
lovastatin
TABLET, EXTENDED RELEASE;ORAL021316-001Jun 26, 2002DISCNNoNo► Subscribe► SubscribeY ► Subscribe
Covis Pharma Bv
ALTOPREV
lovastatin
TABLET, EXTENDED RELEASE;ORAL021316-001Jun 26, 2002DISCNNoNo► Subscribe► Subscribe ► Subscribe
Covis Pharma Bv
ALTOPREV
lovastatin
TABLET, EXTENDED RELEASE;ORAL021316-002Jun 26, 2002RXYesNo► Subscribe► SubscribeY ► Subscribe
Covis Pharma Bv
ALTOPREV
lovastatin
TABLET, EXTENDED RELEASE;ORAL021316-002Jun 26, 2002RXYesNo► Subscribe► Subscribe ► Subscribe
Covis Pharma Bv
ALTOPREV
lovastatin
TABLET, EXTENDED RELEASE;ORAL021316-004Jun 26, 2002RXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: ALTOPREV

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,679,534HMG-CoA reductase inhibitor extended release formulation► Subscribe
6,440,387 Methods for determining risk of Alzheimer's disease► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ALTOPREV

Country Document Number Estimated Expiration
Germany69832092► Subscribe
Australia2004201520► Subscribe
Australia1627599► Subscribe
Australia768950► Subscribe
Austria307572► Subscribe
Canada2315329► Subscribe
Australia759257► Subscribe
Spain2252872► Subscribe
Japan2010229150► Subscribe
Japan2002507564► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Dow
Argus Health
UBS
Harvard Business School
AstraZeneca
Citi
Baxter
Daiichi Sankyo
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot